<div id="readability-page-1"><p><span>Palisade Bio (NASDAQ:PALI - Get Free Report)</span> was downgraded by equities research analysts at Wall Street Zen from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report released on Saturday.</p><p>A number of other equities analysts have also recently commented on the company. Weiss Ratings  reiterated a &#34;sell (e+)&#34; rating on shares of Palisade Bio in a report on Thursday, January 22nd. Citigroup  reiterated a &#34;buy&#34; rating on shares of Palisade Bio in a research note on Tuesday, November 11th. Piper Sandler began coverage on Palisade Bio in a research note on Monday, December 29th. They issued an &#34;overweight&#34; rating and a $25.00 price target on the stock. Clear Str raised shares of Palisade Bio to a &#34;strong-buy&#34; rating in a research report on Monday, December 29th. Finally, B. Riley Financial initiated coverage on shares of Palisade Bio in a report on Friday, January 9th. They issued a &#34;buy&#34; rating and a $7.00 price objective on the stock. One research analyst  has rated the stock with a Strong Buy rating, four have assigned  a Buy rating and one  has given a Sell rating to the company. Based on data from MarketBeat.com, the stock  has an average rating of &#34;Moderate Buy&#34; and an average target price of $16.00.</p><p><b>Get Our Latest Analysis on Palisade Bio</b></p><h2>Palisade Bio Trading Up 9.3%</h2><p>NASDAQ PALI opened at $1.64 on Friday. The company has a market cap of $244.36 million, a PE ratio of -0.77 and a beta of 1.58. Palisade Bio has a 12 month low of $0.53 and a 12 month high of $2.64. The stock has a 50 day moving average of $1.90 and a 200-day moving average of $1.51. </p><p>Palisade Bio (NASDAQ:PALI - Get Free Report) last issued its earnings results on Monday, November 10th. The company reported ($0.38) earnings per share for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.06).  As a group, sell-side analysts predict that  Palisade Bio will post -12.43 EPS for the current fiscal year. </p><h2>Hedge Funds Weigh In On Palisade Bio</h2><p>An institutional investor recently bought a new position in Palisade Bio stock. Total Clarity Wealth Management Inc. acquired a new position in  Palisade Bio, Inc. (NASDAQ:PALI - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 29,935 shares of the company's stock, valued at approximately $70,000. Institutional investors own  11.79% of the company's stock. </p><h2>Palisade Bio Company Profile</h2> (Get Free Report)<p>Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity. </p><p>The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.</p><h2>Read More</h2><ul><li>Five stocks we like better than Palisade Bio</li><li>NEW LAW: Congress Approves Setup For Digital Dollar?</li><li>The day the gold market broke</li><li>What a Former CIA Agent Knows About the Coming Collapse</li><li>Your Bank Account Is No Longer Safe</li><li>He just nailed another gold prediction …</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UEFMSQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UEFMSQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Palisade Bio Right Now?</h2><p>Before you consider Palisade Bio, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Palisade Bio wasn't on the list.</p><p>While Palisade Bio currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

PALI

SBIO

ARKG

<p>Wall Street Zen has downgraded Palisade Bio (NASDAQ:PALI) from a "hold" to a "sell" rating. Other analysts have mixed views, with Weiss Ratings maintaining a "sell (e+)" and Citigroup a "buy" rating. The stock has an average rating of "Moderate Buy" with a target price of $16.00. Palisade Bio's market cap is $244.36 million, and it reported a loss of ($0.38) EPS, missing estimates. The company focuses on localized immunotherapies for cancer and inflammatory diseases, with its lead product in clinical trials.</p>

Palisade Bio (NASDAQ:PALI) Lowered to Sell Rating by Wall Street Zen